15-20 National Hospital
Company
15-20 National Hospital develops one asset, in phase 1 (GS030 in retinitis pigmentosa). Mostly gene therapy.
- 1
- Asset
- Furthest stage
- Phase 1
- 0
- Trials
- 1
- Signal
Pipeline
1Optogenetic gene therapy encoding a channelrhodopsin to restore light sensitivity in retinal ganglion cells
Phase 1, Gene therapy, retinitis pigmentosa, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Signals1
- Similar companies5